NCT05413655

A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease

A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Oral EX039 As Add-on to Acetylcholine Esterase Inhibitors in Subjects with Mild Alzheimer's Disease

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Excelsior · Industry
• Sex: All
• Age: 50 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2, randomized, double-blind, placebo-controlled study of oral EX039 as add-on to Acetylcholine Esterase Inhibitors in subjects with mild Alzheimer's disease.

Conditions

• Alzheimer Disease

Interventions

Type	Name	Description
DRUG	EX039	The dosage form of EX039 is the capsule for oral use
DRUG	Placebo	The dosage form of Placebo is the capsule for oral use

Timeline

• Start date: 2022-08-08
• Primary completion: 2026-12-31
• Completion: 2027-02-01
• First posted: 2022-06-10
• Last updated: 2025-02-26

Locations

1 site across 1 country: Taiwan